Indicio Launches Indicio Proven Availability in AWS Marketplace
When it comes to data, "verify once and reuse often" is the key to reducing cost, improving efficiency, and delivering a much better user experience, whether its passwordless access, know your customer (KYC), or zero trust access management. By using verifiable credentials to share data and identity, information can be authenticated without checking in with its source, meaning time-consuming manual processes reliant on trustworthy data can be instant and automated.
AWS customers will now have access to Indicio Proven's award-winning privacy and security features to manage biometrics and avoid deepfakes directly within
"With Indicio Proven, we've created a product that will drive digital evolution across every sector," said
Indicio Proven is now generally available in
About Indicio
Indicio is the global market leader in decentralized identity technology, delivering the software and infrastructure needed for organizations to create and share instantly verifiable data. Indicio Proven® is Indicio's award-winning flagship product that provides a complete, out-of-the-box solution to add seamless, secure, privacy-compliant digital processes to existing systems and data sources. Indicio-powered solutions are transforming business and the public sector across agriculture, government, education, financial services, healthcare, and travel and hospitality. Learn how you can unlock the power of verifiable identity and data at Indicio.tech.
Media:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/indicio-launches-indicio-proven-availability-in-aws-marketplace-302150707.html
SOURCE Indicio
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parksy (parksy.com) Mapped Parking Around 12 of America's Biggest Venues: Nearly 2,000 Options Near Madison Square Garden, 18 Near Hard Rock Stadium
- Encrypted Phone Vault Vaultaire Makes Client-Side Cloud Backup Free for Every User
- Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share